1. Home
  2. FRME vs AVDL Comparison

FRME vs AVDL Comparison

Compare FRME & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Merchants Corporation

FRME

First Merchants Corporation

HOLD

Current Price

$37.20

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Avadel Pharmaceuticals plc

AVDL

Avadel Pharmaceuticals plc

HOLD

Current Price

$21.49

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRME
AVDL
Founded
1893
2015
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
FRME
AVDL
Price
$37.20
$21.49
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$47.33
$18.38
AVG Volume (30 Days)
286.7K
1.4M
Earning Date
01-29-2026
11-04-2025
Dividend Yield
3.84%
N/A
EPS Growth
32.99
N/A
EPS
4.00
N/A
Revenue
$649,589,000.00
$248,517,000.00
Revenue This Year
$13.81
$65.47
Revenue Next Year
$14.43
$30.88
P/E Ratio
$9.36
N/A
Revenue Growth
9.53
79.88
52 Week Low
$33.13
$6.38
52 Week High
$45.62
$23.57

Technical Indicators

Market Signals
Indicator
FRME
AVDL
Relative Strength Index (RSI) 44.88 57.30
Support Level $38.06 $21.50
Resistance Level $38.96 $21.60
Average True Range (ATR) 0.59 0.11
MACD -0.20 -0.09
Stochastic Oscillator 21.36 42.65

Price Performance

Historical Comparison
FRME
AVDL

About FRME First Merchants Corporation

First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: